Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 11/20 | 0.61 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6278869 | 0.86 | — | — | |
| SCHEMBL19917043 | 0.79 | NOS2 (0.39) | NOS2AAK1 | |
| SCHEMBL24460474 | 0.78 | — | — | |
| SCHEMBL6128483 | 0.77 | KDM4E (0.42) | NOS2AAK1 | |
| SCHEMBL14755201 | 0.77 | KDM4E (0.42) | NOS2AAK1 | |
| SCHEMBL18787204 | 0.77 | KDM4E (0.42) | NOS2AAK1 | |
| SCHEMBL18583477 | 0.77 | KDM4E (0.42) | NOS2AAK1 | |
| SCHEMBL600016 | 0.77 | KDM4E (0.42) | NOS2AAK1 | |
| SCHEMBL19957485 | 0.77 | NOS2 (0.37) | NOS2AAK1 | |
| SCHEMBL15542255 | 0.77 | KDM4E (0.42) | NOS2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855726-B1 | Quinolones as serine protease inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-15 | — | — | US | claimed |
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | BERRYMAN KENT ALAN (US) | 2003-10-02 | — | — | US | claimed |
| US-6509335-B1 | This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of | WARNER-LAMBERT COMPANY | 2003-01-21 | — | — | US | claimed |
| US-20020086866-A1 | Quinoxalinones as serine protease inhibitors | DUDLEY DANETTE ANDREA (US) | 2002-07-04 | — | — | US | claimed |
| US-6410536-B1 | ANTICOAGULANTS | WARNER-LAMBERT COMPANY | 2002-06-25 | — | — | US | claimed |
| EP-1091955-A1 | QUINOLONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-04-18 | — | — | EP | claimed |
| EP-1068190-A1 | QUINOXALINONES AS SERINE PROTEASE INHIBITORS SUCH AS FACTOR XA AND THROMBIN | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-17 | — | — | EP | claimed |
| EP-1068191-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-17 | — | — | EP | claimed |
| WO-1999050254-A1 | QUINOXALINONES AS SERINE PROTEASE INHIBITORS SUCH AS FACTOR XA AND THROMBIN | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | claimed |
| WO-1999050257-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | claimed |
| WO-1999050263-A1 | QUINOLONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | claimed |
| US-6916805-B2 | Quinoxalinones as serine protease inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-07-12 | — | — | US | disclosed |
| US-6855726-B1 | Quinolones as serine protease inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-15 | — | — | US | disclosed |
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | BERRYMAN KENT ALAN (US) | 2003-10-02 | — | — | US | disclosed |
| US-6509335-B1 | This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of | WARNER-LAMBERT COMPANY | 2003-01-21 | — | — | US | disclosed |
| US-6410536-B1 | ANTICOAGULANTS | WARNER-LAMBERT COMPANY | 2002-06-25 | — | — | US | disclosed |
| EP-1091955-A1 | QUINOLONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-04-18 | — | — | EP | disclosed |
| EP-1068191-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999050257-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
| WO-1999050263-A1 | QUINOLONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086866-A1 | Quinoxalinones as serine protease inhibitors | HABP2, SERPINB1, PRSS1 | NOS2 3231/4885AAK1 2933/4885NOS3 2226/4885 |
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | HABP2, SPINT2, SERPINB1 | NOS2 4470/4885AAK1 2757/4885NOS3 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.